Macci raises $1.5M angel round for biomagnetic beads
What's the deal? Chinese startup Macci has closed an angel round of US$1.38M to advance the development and manufacturing of high-performance biomagnetic beads. The company centres on its MyTron™ bead platform, which serves precision medicine, in-vitro diagnostics (IVD), drug discovery, and regenerative medicine.
What's the endgame? Macci aims to supply domestically controlled separation materials and solutions for these fields. It will use the funding to localise core materials, develop functional products, and run customer application validation.
Why now? Investors are still backing the localization of IVD raw materials in China, where established domestic magnetic-bead suppliers already compete across nucleic-acid extraction, cell selection, and other research workflows. Macci, founded in recent years by a team with a materials science and biotechnology background, is targeting a specialized niche: nanoscale beads with low nonspecific binding.
What could go wrong? The angel round is small next to recent raises in the sector, such as Boyi BioDealroom has a profile for this one. Try Dealroom →'s nearly US$13.8M Series B. Its significance will hinge on whether independent customers validate the materials and move from trials to repeat orders.
The signal: At this stage, Macci is an early commercialization bet rather than proof of a market breakthrough — but it reflects continued investor appetite for homegrown alternatives to imported diagnostic inputs.
Read more: donews.com
Image credit: Generated with Gemini
